Karveel has developed a new class of antimicrobial compounds derived from the natural antibiotic nisin (J. Am. Chem. Soc. 2015, 137, 9382-9389). Nisin is transformed through chemical modifications to generate highly stable and active antibacterial lipopeptides with superior drug-like properties. We are developing the lead compound SNP021062 as a therapy for VRE bacteremia/endocarditis. Additional early stage projects are aimed at addressing multi-drug resistant Gram-negative pathogens.